Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HSV1-dICP0 |
Synonyms | |
Therapy Description |
HSV1-dICP0 is an oncolytic herpes simplex virus type 1 with deletion of the ICP0 gene, which may induce a cytotoxic response in tumor cells (PMID: 33593882). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HSV1-dICP0 | HSV1-dICP0 is an oncolytic herpes simplex virus type 1 with deletion of the ICP0 gene, which may induce a cytotoxic response in tumor cells (PMID: 33593882). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 LOH JAK2 inact mut | melanoma | predicted - sensitive | HSV1-dICP0 | Preclinical - Patient cell culture | Actionable | In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, HSV1-dICP0, in culture (PMID: 33593882). | 33593882 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|